| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_682d6117f1aef86a7b2b9af096d7d98a |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D407-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D407-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-06 |
| filingDate |
2013-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f05dc4adf4135e8dd4edd9fbec8df7a7 |
| publicationDate |
2013-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2013126156-A1 |
| titleOfInvention |
Nitric oxide donating selective glucocorticoid receptor agonist compounds and ophthalmic compositions |
| abstract |
A compound and composition useful in the treatment of ocular inflammation or prevention of glaucoma or its progression comprising a nitric oxide donating selective glucocorticoid receptor agonist ("NO donating SEGRA"), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof. The composition can comprise an additional anti-inflammatory agent and can be formulated for topical application, injection, or implantation. It may be used in combination with another therapy directed to reducing intraocular pressure or ocular inflammation. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020152193-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111060638-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114957279-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114957279-A |
| priorityDate |
2012-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |